Immune Thrombocytopenia at a Crossroads: New Therapies Aim to Replace Stopgap Treatments | Competitive Intelligence
ITP affects 2–5/100k yearly. New therapies like BTK, FcRn blockers aim for lasting remission, fewer side effects, and may challenge injectable TPO-RA dominance. AUSTIN, TX, UNITED STATES, June 10, 2025 /EINPresswire.com/ -- Immune Thrombocytopenia (ITP …